Jason John Luke

87PUBLICATIONS
322CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapyMolecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (87)

|Jul 02, 2026
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

|Feb 11, 2026
Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumors.

John L Villano, Jason J Luke, Ricklie Julian

|Nov 26, 2025
Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors.

Benjamin T Cooper, Wade T Iams, David B Page

|Nov 03, 2025
IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma.

David H Aggen, Meredith McKean, Jean H Hoffman-Censits

|Jun 15, 2025
Multiomics identifies tumor-intrinsic SREBP1 driving immune exclusion in hepatocellular carcinoma.

Rebekah E Dadey, Ruxuan Li, Jake Griner

|Jun 11, 2025
And… We're Back: The Reemergence of CD137 in Cancer Immunotherapy via Antigen Anchoring.

Matthew K Nguyen, Jason J Luke

Pageof 15

Frequent Collaborators

12 joint publications

Riyue Bao

8 joint publications

Diwakar Davar

5 joint publications

Georgina V Long

5 joint publications

Dirk Schadendorf